Jon Marc Wigginton

Person

Collegeville, PA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Combination therapy for the treatment of cancer
- Patent number 11,174,315
- Issue date Nov 16, 2021
- MacroGenics, Inc.
- James Vasselli
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination therapy for the treatment of cancer
- Patent number 11,078,279
- Issue date Aug 3, 2021
- MacroGenics, Inc.
- Jon Marc Wigginton
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
- Patent number 10,688,180
- Issue date Jun 23, 2020
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,604,575
- Issue date Mar 31, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,584,170
- Issue date Mar 10, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,577,423
- Issue date Mar 3, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,092
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,093
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,091
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,090
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,308,714
- Issue date Jun 4, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,596
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,594
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,595
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,138,299
- Issue date Nov 27, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,072,082
- Issue date Sep 11, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 9,856,320
- Issue date Jan 2, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
- Patent number 9,789,182
- Issue date Oct 17, 2017
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies that bind PD-L1 and uses thereof
- Patent number 9,212,224
- Issue date Dec 15, 2015
- Bristol-Myers Squibb Company
- John Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE
- Publication number 20230312756
- Publication date Oct 5, 2023
- MacroGenics, Inc.
- Bradley James SUMROW
- C07 - ORGANIC CHEMISTRY
Information Patent Application
METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN...
- Publication number 20230226206
- Publication date Jul 20, 2023
- MacroGenics, Inc.
- Gerry Chester BOHAC
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Therapy for the Treatment of Cancer
- Publication number 20230056230
- Publication date Feb 23, 2023
- MacroGenics, Inc.
- Bradley James Sumrow
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatmen...
- Publication number 20220213203
- Publication date Jul 7, 2022
- MacroGenics, Inc.
- Jan Kenneth Davidson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination Therapy for the Treatment of Cancer
- Publication number 20220204625
- Publication date Jun 30, 2022
- MacroGenics, Inc.
- James Vasselli
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination Therapy for the Treatment of Cancer
- Publication number 20220041725
- Publication date Feb 10, 2022
- MacroGenics, Inc.
- Jon Marc Wigginton
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatm...
- Publication number 20210061911
- Publication date Mar 4, 2021
- MacroGenics, Inc.
- Jon Marc Wigginton
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION THERAPY
- Publication number 20200255524
- Publication date Aug 13, 2020
- MacroGenics, Inc.
- Ezio Bonvini
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-PD-1 ANTIBODIES AND USES THEREOF
- Publication number 20200095322
- Publication date Mar 26, 2020
- INCYTE CORPORATION
- Mark Cornfeld
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Combination Therapy for the Treatment of Cancer
- Publication number 20190389952
- Publication date Dec 26, 2019
- MacroGenics, Inc.
- James Vasselli
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Methods for the Use of CD32B x CD79B-Binding Molecules in the Treat...
- Publication number 20190322741
- Publication date Oct 24, 2019
- MacroGenics, Inc.
- Wei Chen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190153099
- Publication date May 23, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190135920
- Publication date May 9, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112377
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112376
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100589
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100590
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190092863
- Publication date Mar 28, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180319887
- Publication date Nov 8, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180312590
- Publication date Nov 1, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination Therapy for the Treatment of Cancer
- Publication number 20180298100
- Publication date Oct 18, 2018
- MacroGenics, Inc.
- Jon Marc Wigginton
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282413
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282414
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180273624
- Publication date Sep 27, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
- Publication number 20180117147
- Publication date May 3, 2018
- Bristol-Myers Squibb Company
- Robert F. GRAZIANO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...
- Publication number 20180099045
- Publication date Apr 12, 2018
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20160090417
- Publication date Mar 31, 2016
- Bristol-Myers Squibb Company
- JOHN P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...
- Publication number 20150290316
- Publication date Oct 15, 2015
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
- Publication number 20150283234
- Publication date Oct 8, 2015
- BRISTOL-MYERS SQUIBB COMPANY
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20150125463
- Publication date May 7, 2015
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING

Jon Marc Wigginton

Person

Patents Grantslast 30 patents

Combination therapy for the treatment of cancer

Combination therapy for the treatment of cancer

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Antibodies that bind PD-L1 and uses thereof

Patents Applicationslast 30 patents

METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE

METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN...

Therapy for the Treatment of Cancer

Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatmen...

Combination Therapy for the Treatment of Cancer

Combination Therapy for the Treatment of Cancer

Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatm...

COMBINATION THERAPY

ANTI-PD-1 ANTIBODIES AND USES THEREOF

Combination Therapy for the Treatment of Cancer

Methods for the Use of CD32B x CD79B-Binding Molecules in the Treat...

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Combination Therapy for the Treatment of Cancer

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER

COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...

COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING